IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC
ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY

a 2022

IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY

BEHRENS, F.; P. C. TAYLOR; D. WETZEL; N. C. BRUN; J. BRANDT-JUERGENS et al.

Základní údaje

Originální název

IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY

Autoři

BEHRENS, F.; P. C. TAYLOR; D. WETZEL; N. C. BRUN; J. BRANDT-JUERGENS; E. DRESCHER; Eva DOKOUPILOVÁ; A. ROWINSKA-OSUCH; N. Abdel-Kader MARTIN a K. DE VLAM

Vydání

2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 27.400

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14160/22:00128084

Organizační jednotka

Farmaceutická fakulta

ISSN

DOI

https://doi.org/10.1136/annrheumdis-2022-eular.536

UT WoS

000850279000259

Klíčová slova anglicky

Izokibep; ABY-035; psoriatic arthriris; clinical trial

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam

Změněno: 19. 1. 2023 09:27, JUDr. Sabina Gajdzioková

Anotace

V originále

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis). In addition, PsA is commonly associated with comorbidities such as metabolic syndrome and cardiovascular diseases where IL-17 is a key driver of this disease. Izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution. Here, we report 16-week phase 2 results in patients with active PsA.

Citovat

BEHRENS, F.; P. C. TAYLOR; D. WETZEL; N. C. BRUN; J. BRANDT-JUERGENS; E. DRESCHER; Eva DOKOUPILOVÁ; A. ROWINSKA-OSUCH; N. Abdel-Kader MARTIN a K. DE VLAM. IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY. 2022. ISSN 0003-4967. Dostupné z: https://doi.org/10.1136/annrheumdis-2022-eular.536.

@proceedings{2247562,
   author = {Behrens, F. and Taylor, P. C. and Wetzel, D. and Brun, N. C. and BrandtandJuergens, J. and Drescher, E. and Dokoupilová, Eva and RowinskaandOsuch, A. and Martin, N. AbdelandKader and de Vlam, K.},
   doi = {https://doi.org/10.1136/annrheumdis-2022-eular.536},
   keywords = {Izokibep; ABY-035; psoriatic arthriris; clinical trial},
   language = {eng},
   title = {IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY},
   url = {https://ard.bmj.com/content/81/Suppl_1/170},
   year = {2022}
}

TY  - CONF
ID  - 2247562
AU  - Behrens, F. - Taylor, P. C. - Wetzel, D. - Brun, N. C. - Brandt-Juergens, J. - Drescher, E. - Dokoupilová, Eva - Rowinska-Osuch, A. - Martin, N. Abdel-Kader - de Vlam, K.
PY  - 2022
TI  - IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
KW  - Izokibep
KW  - ABY-035
KW  - psoriatic arthriris
KW  - clinical trial
UR  - https://ard.bmj.com/content/81/Suppl_1/170
N2  - Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis). In addition, PsA is commonly associated with comorbidities such as metabolic syndrome and cardiovascular diseases where IL-17 is a key driver of this disease. Izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution. Here, we report 16-week phase 2 results in patients with active PsA.
ER  -

BEHRENS, F.; P. C. TAYLOR; D. WETZEL; N. C. BRUN; J. BRANDT-JUERGENS; E. DRESCHER; Eva DOKOUPILOVÁ; A. ROWINSKA-OSUCH; N. Abdel-Kader MARTIN a K. DE VLAM. \textit{IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY}. 2022. ISSN~0003-4967. Dostupné z: https://doi.org/10.1136/annrheumdis-2022-eular.536.

Přehled o publikaci